Scientists at BC Children’s Hospital and the University of British Columbia have developed a gene therapy that programs a type of immune cell called T regulatory cells (Tregs) to protect transplanted tissues from rejection by the patient’s immune system.
The proof-of-concept study is published today in the Journal of Clinical Investigation print issue.
“With further research, Tregs could be given as a living drug to prevent immune attack of transplanted cells and organs,” says Dr. Megan Levings, the study’s principal investigator.
Dr. Levings is a scientist at the Child & Family Research Institute (CFRI) at BC Children’s Hospital where she leads the Childhood Diseases research theme, and she is a professor in the Department of Surgery at the University of British Columbia (UBC).
“This exciting discovery is the first step towards testing these cells in humans undergoing transplantation,” says Dr. Levings.
After transplantation, the patient’s body sometimes identifies the transplanted tissue as foreign and mounts an immune attack against it. For this reason, most transplant patients must take immune-suppressing medications for the rest of their lives.
In 2014, there were 2,433 solid organs transplanted in Canada and from 2010-2015, there were 52 pediatric solid organ transplants performed in British Columbia.
For this study, the scientists removed Tregs from blood donated by volunteers to the Canadian Blood Services. The scientists built a gene that makes a protein called CAR (chimeric antigen receptor). They used a harmless virus to insert the CAR gene into Tregs, which programmed the cells to recognize specific proteins commonly found on the surface of transplanted tissues. The normal role of Tregs is to turn off the immune response and prevent an immune response to healthy tissues. The scientists did a series of experiments that proved the modified Tregs could recognize transplanted tissues and protect them from the immune system.
A related concept is used in a type of cancer treatment called immunotherapy where the patient’s own immune cells are genetically programmed with the CAR gene to mount an immune response against tumour cells.
“We took this approach from cancer immunotherapy and we used it for the opposite purpose – to turn off unwanted immune responses,” says Dr. Levings.
“It’s a whole new age in medicine, and we’re doing cutting edge work right here in BC,” says Dr. Katherine MacDonald, the study’s first author. The research was the basis of Dr. MacDonald’s doctoral thesis while she was a UBC trainee supervised by Dr. Levings at CFRI.
“With this finding, it opens up the possibility to build a gene for any disease where the immune system is overactive,” says Dr. MacDonald.
This includes autoimmune diseases, which develop when the immune system destroys healthy tissues such as the insulin-producing cells of the pancreas in Type 1 diabetes or cells of the intestinal lining in inflammatory bowel disease.
The researchers say a decade of further work is needed to develop safe and targeted treatments using modified Tregs.
The Latest on: Transplant rejection
via Google News
The Latest on: Transplant rejection
- Dr. Yasmin Mohseni Announces Groundbreaking Treatment for Autoimmune Diseases and Solid Organ Transplantson August 1, 2022 at 10:23 am
Dr. Yasmin Mohseni, an immunologist at USC's Keck School of Medicine who specializes in research and clinical translation of immunotherapeutics, recently announced that companies are pursuing ...
- Eledon Secures FDA Clearance For Kidney Transplant Rejection Studyon August 1, 2022 at 4:34 am
The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ: ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ ...
- University of California, Los Angeles: UCLA awarded $11.5 million to improve organ, hand and face transplantationon July 29, 2022 at 4:20 am
The Dumont–UCLA Transplant Center has received two grants totaling $11.5 million from the federal government for research aimed at making donated organs last longer and helping transplant recipients ...
- CAFC Affirms Invalidation of Stanford Organ Transplant Rejection Test in Latest Patent-Eligibility Blow to Medical Diagnosticson July 19, 2022 at 1:30 pm
On July 18, the U.S. Court of Appeals for the Federal Circuit issued a precedential decision in CareDx, Inc. v. Natera, Inc. affirming a summary judgment ruling of the District of Delaware, which ...
- Bone Marrow Transplant Rejection Treatment Market Is Set to Fly High in Years to Come with Top Countries Dataon July 19, 2022 at 4:33 am
Jul 19, 2022 (The Expresswire) -- "Bone Marrow Transplant Rejection Treatment Market" Insights 2022 By Types, Applications, Regions and Forecast to 2028.
- The successful transplantation of genetically engineered pig hearts into recently deceased humanson July 14, 2022 at 12:59 am
Researchers successfully transplanted two genetically engineered heart pigs into recently deceased humans in June and July 2022, marking the most recent advancement in addressing the nationwide ...
- Oncocyte Announces Market Entry And Early Adopter Program For Transplant Rejection Monitoring Businesson July 13, 2022 at 5:41 am
The test can serve an important need in managing transplant patients. It is a simple and non-invasive blood test that has been shown to accurately rule-out rejection or injury following transplant ...
- Surgeons Successfully Transplant Pig Hearts Into Dead Humanson July 13, 2022 at 12:34 am
The team first modified 10 of the pig donors’ genes in order to reduce the risk of transplant rejection and maintain compatibility with a human chest cavity. The operating room where the ...
- 2 more gene-edited pig hearts were just successfully transplanted into humans — an early sign that pig transplants could really workon July 11, 2022 at 5:01 pm
Four of the gene edits were porcine, to prevent transplant rejection and abnormal growth, and six were human transgenes, designed to make human and pig parts more compatible. "It really is the ...
- Bone Marrow Transplant Rejection Treatment Market Size, Share & COVID-19 Impact Analysis, By Type, By Application, and Regional Forecast, 2022-2028on July 4, 2022 at 12:54 am
The Bone Marrow Transplant Rejection Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share ...
via Bing News